Medscape is available in 5 Language Editions – Choose your Edition here.


Mycobacterium Avium-Intracellulare Workup

  • Author: Janak Koirala, MD, MPH, FACP, FIDSA; Chief Editor: Michael Stuart Bronze, MD  more...
Updated: Oct 06, 2015

Approach Considerations

In patients who may have pulmonary infection with Mycobacterium avium complex (MAC), diagnostic testing includes acid-fast bacillus (AFB) staining and culture of sputum specimens. If disseminated MAC (DMAC) infection is suspected, culture specimens should also include blood and urine. Stool cultures can be collected if diarrhea is present. Cutaneous lesions should be cultured.

Imaging studies of the chest should be performed to assess pulmonary involvement.

In patients with DMAC, a complete blood count (CBC) often shows anemia and occasionally pancytopenia due to bone marrow suppression secondary to the infection, although either leukocytosis or leukopenia may be present. Hypogammaglobulinemia may be found. On liver function studies, patients with DMAC usually have elevated transaminase and alkaline phosphatase levels.

An enzyme immunoassay (EIA) kit used in Japan has been used to detect serum IgA antibody to MAC-specific glycopeptidolipid core antigen. This could be useful for serodiagnosis of MAC pulmonary infection. Sensitivity and specificity of this EIA kit were reported as 84% and 100%, respectively.[17] Other serological tests are also currently under investigation.

If pulmonary or disseminated MAC infection is suspected, an HIV test should be performed.

Diagnosis of MAC lymphadenitis in children generally involves lymph node biopsy or complete excision of lymph nodes. Skin testing (MAC tuberculin test) contributes very little in establishing diagnosis.

The American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) have issued guidelines for the diagnosis, treatment, and prevention of nontuberculous mycobacterial pulmonary infection.[18]


ATS/IDSA Diagnostic Guidelines

The ATS/IDSA guidelines include clinical, radiographic, and bacteriologic criteria to establish a diagnosis of nontuberculous mycobacterial lung disease.[18]

Clinical criteria are as follows:

  • Pulmonary signs and symptoms such as cough, fatigue, weight loss; less commonly, fever and weight loss; dyspnea
  • Appropriate exclusion of other diseases (eg, carcinoma, tuberculosis)

Radiographic criteria are as follows:

  • Chest radiograph with nodular or cavitary opacities
  • High-resolution computerized tomography (HRCT) scan showing multifocal bronchiectasis and multiple small nodule

Bacteriologic criteria are as follows:

  • At least 2 culture-positive sputum samples
  • At least one culture-positive bronchial washing or lavage
  • Biopsy with histopathologic features consistent with mycobacterial infections (eg, granulomatous inflammation or positive AFB stain) and positive culture result (sputum, endobronchial, or biopsy specimen)

Patient must meet at least one of the bacteriologic criteria within 1 year.

The ATS/IDSA guidelines recommend basing the diagnosis of hot-tub lung (hypersensitivity pneumonitis-like lung disease) on a compatible clinical picture, including hot-tub exposure, microbiological data, radiographic findings, and histopathology. In the absence of histopathology, evidence for hot-tub lung needs to include the following:

  • Subacute onset of respiratory symptoms
  • Hot-tub exposure
  • Characteristic radiologic changes
  • Isolation of MAC from sputum, bronchoalveolar lavage (BAL), lung tissue, and hot-tub water

Characteristic radiologic changes include ground-glass opacities, centrilobular nodules, and air trapping on expiratory CT scans.

In a study that evaluated the significance of positive sputum culture results using ATS guidelines for the diagnosis of NTM infection, only 7 of 46 (15%) patients infected with HIV and 1 of 34 (3%) patients without HIV infection but with MAC-positive sputum met the clinical, bacteriologic, and radiographic criteria for MAC pulmonary disease.


Acid-Fast Bacillus Stains and Cultures

At least 3 sputum specimens, preferably early-morning samples taken on different days, should be collected for AFB staining and culture. Sputum AFB stains are positive for MAC in most patients with pulmonary MAC infection. Mycobacterial cultures grow MAC in about 1-2 weeks, depending on the culture technique and bacterial burden.

If patient is unable to produce sputum, sputum induction may be helpful in obtaining respiratory tract sample. Procedures such as bronchoscopy with bronchoalveolar lavage (BAL) with or without biopsy may be necessary to obtain appropriate respiratory specimen.

Interpretation of sputum AFB stain and culture may be difficult, as MAC can colonize the respiratory tract without causing clinical infection. See the American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA) guidelines for clinical interpretation of culture results.

The species-specific molecular probes are used for rapid identification of mycobacterial species grown in culture (eg, Mycobacterium tuberculosis, M kansasii, MAC). Various nucleic acid amplification techniques (eg, polymerase chain reaction [PCR], ligase chain reaction, transcription-mediated amplification) are also used for this purpose, as well as for direct detection of mycobacteria in the sputum. However, these assays need further refinement to improve their sensitivity to detect mycobacteria directly in patient's specimens.

Mycobacterial susceptibility testing for various antimycobacterial agents is available in specialized laboratories. Because studies have shown poor correlations between in vitro susceptibility results and clinical outcome, the ATS/IDSA guidelines recommend routine antibiotic susceptibility testing for clarithromycin only. Based on the experience at the author's institution, susceptibility tests are reliable if performed selectively at highly experienced laboratories that specialize in mycobacteriology.

MAC may be isolated from the sputum of immunocompetent patients without any evidence of lung disease. Transient MAC colonization was reported in up to 11% of patients with tuberculosis in the 1950s. Repeated isolation of MAC from sputum, even in the absence of obvious lung disease, may signify an underlying slow progression of lung disease.

Blood cultures

Blood cultures in appropriate mycobacterial culture media should be performed for suspected disseminated MAC (DMAC) infection. This should be performed routinely in patients with advanced AIDS and persistent undiagnosed febrile illness. Cultures generally take 1-2 weeks to turn positive. Early in the course of infection, bacteremia may be low-level or intermittent, possibly causing false-negative blood culture results. Later in the course of infection, blood cultures results are invariably positive.


Chest Radiography and Computed Tomography

Chest radiography is indicated to assess pulmonary involvement if disseminated disease is suspected. One series found that 8 of 11 cases of DMAC infection with cutaneous involvement had positive results on chest radiographs.

Chest radiography generally reveals MAC pulmonary lesion s. However, in cases with limited lung infection, CT scanning of the chest and even high-resolution CT (HRCT) scanning are needed to reveal the lung lesions. HRCT scanning has been shown to be more sensitive than chest radiography for revealing pulmonary abnormalities associated with MAC infection.

Patients with pulmonary MAC infection with underlying lung disease often have cavities revealed by imaging studies. Typically, these patients have fibrocavitary changes and nodules that involve the upper lung zones.

Elderly women without underlying lung disease but with MAC pulmonary infection develop a fibronodular bronchiectasis that often involves the lingula and right middle lobe. A strong association between MAC infection and bronchiectasis with circumscribed nodules has been shown in these patients. Surveys of patients with fibronodular bronchiectasis have documented MAC infection in 25-50% of patients.

Other radiological changes include atelectasis, consolidation, tree-in-bud appearance, and ground-glass opacities.

In patients with AIDS and DMAC infection, CT scan of the abdomen reveals retroperitoneal or periaortic lymphadenopathy and hepatosplenomegaly.

Hypersensitivity pneumonitis-like changes characterized by ground-glass attenuation, centrilobular nodules, and air trapping on expiratory images are seen on CT scans in patients with hot-tub lung, which is a type of hypersensitivity pneumonitis-like syndrome described in patients exposed to aerosolized MAC.



Bronchoscopy and transbronchial biopsy may be needed to diagnose pulmonary MAC infection. Alternatively, a CT-guided needle biopsy, video-assisted thoracoscopic (VAT) biopsy, or open lung biopsy may be performed, depending on the size and location of the lesion.

Procedures that may be helpful to establish diagnosis of DMAC infection in patients with AIDS include lymph node biopsy, bone marrow biopsy, and liver biopsy. These procedures are indicated if the blood cultures fail to grow the mycobacteria. They are also helpful to exclude other causes of lymphadenopathy, anemia, or pancytopenia. Liver biopsy is rarely necessary to establish a diagnosis of MAC infection.

Diagnosis of MAC lymphadenitis is based on a high level of clinical suspicion and biopsy or complete excision of involved nodes with histological and microbiological confirmation. Fine-needle aspiration of lymph nodes has been used to obtain tissue for diagnosis when complete excision is not feasible (eg, for inaccessible nodes, such as those that overlie the facial nerve).

Results of acid-fast staining of tissue or pus are usually negative because of the small number of bacilli present. The culture result may take a few weeks to become positive. Nucleic acid amplification methods can provide a more rapid diagnosis.

Biopsy should be performed in patients with cutaneous lesions. Tissue samples may be obtained for histopathologic evidence of mycobacterial infection, and staining with Ziehl-Neelsen stain may reveal acid-fast bacilli.


Histologic Findings

Histologic findings of MAC infection include necrotizing and nonnecrotizing granulomas and positive AFB smear results. Numbers of AFB are usually higher in MAC infection than in M tuberculosis infection. Patients with HIV/AIDS have evidence of DMAC infection in multiple organs, but granuloma formation is less common. DMAC infection in patients with AIDS typically demonstrates the presence of sheets of macrophages laden with AFB.

Histologic findings of lymph node biopsies in children infected with MAC in a reported series generally showed bright eosinophilic serpiginous necrosis with nuclear debris scattered throughout the necrotic foci. Most of these cases also had Langhans-type giant cells, but infiltration by plasma cells and neutrophils was not consistently observed.

Patients with hypersensitivity pneumonitis secondary to MAC infection show multiple well-formed nonnecrotizing granulomas positive for AFB.

Contributor Information and Disclosures

Janak Koirala, MD, MPH, FACP, FIDSA Professor and Division Chair, Division of Infectious Diseases, Department of Internal Medicine, Southern Illinois University School of Medicine

Janak Koirala, MD, MPH, FACP, FIDSA is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Society for Microbiology, International AIDS Society, International Society for Infectious Diseases, International Society of Travel Medicine, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Aaron Glatt, MD Chief Administrative Officer, Executive Vice President, Mercy Medical Center, Catholic Health Services of Long Island

Aaron Glatt, MD is a member of the following medical societies: American College of Chest Physicians, American Association for Physician Leadership, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Infectious Diseases Society of America, International AIDS Society, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, Oklahoma State Medical Association, Southern Society for Clinical Investigation, Association of Professors of Medicine, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Additional Contributors

Klaus-Dieter Lessnau, MD, FCCP Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, Society of Critical Care Medicine

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author William B Harley, MD,to the development and writing of the source article.

  1. Nishiuchi Y, Maekura R, Kitada S, et al. The recovery of Mycobacterium avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC. Clin Infect Dis. 2007 Aug 1. 45(3):347-51. [Medline].

  2. Dhillon SS, Watanakunakorn C. Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium complex infection due to voluntary cough suppression. Clin Infect Dis. 2000 Mar. 30(3):572-5. [Medline].

  3. Hartman TE, Jensen E, Tazelaar HD, et al. CT findings of granulomatous pneumonitis secondary to Mycobacterium avium-intracellulare inhalation: "hot tub lung". AJR Am J Roentgenol. 2007 Apr. 188(4):1050-3. [Medline].

  4. Sood A, Sreedhar R, Kulkarni P, Nawoor AR. Hypersensitivity pneumonitis-like granulomatous lung disease with nontuberculous mycobacteria from exposure to hot water aerosols. Environ Health Perspect. 2007 Feb. 115(2):262-6. [Medline].

  5. Feller M, Huwiler K, Stephan R, et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis. 2007 Sep. 7(9):607-13. [Medline].

  6. Koirala J, Adamski A, Koch L, Stueber D, El-Azizi M, Khardori NM, et al. Interferon-gamma receptors in HIV-1 infection. AIDS Res Hum Retroviruses. 2008 Aug. 24(8):1097-102. [Medline].

  7. Koh WJ, Jeong BH, Jeon K, Lee NY, Lee KS, Woo SY, et al. Clinical Significance of the Differentiation between Mycobacterium avium and Mycobacterium intracellulare in M. avium Complex Lung Disease. Chest. 2012 May 24. [Medline].

  8. Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest. 2007 Apr. 131(4):1166-72. [Medline].

  9. Mycobacterium avium Complex. Centers for Disease Control and Prevention. Available at Accessed: August 15, 2011.

  10. Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis. 2009 Dec 15. 49(12):e124-9. [Medline].

  11. Maugein J, Dailloux M, Carbonnelle B, et al. Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease. Eur Respir J. 2005 Dec. 26(6):1092-6. [Medline].

  12. Freeman J, Morris A, Blackmore T, et al. Incidence of nontuberculous mycobacterial disease in New Zealand, 2004. N Z Med J. 2007 Jun 15. 120(1256):U2580. [Medline].

  13. Han XY, Tarrand JJ, Infante R, et al. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol. 2005 Sep. 43(9):4407-12. [Medline].

  14. Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis. 1999 May. 28(5):1080-5. [Medline].

  15. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic Factors of 634 HIV-Negative Patients with Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med. 2012 Mar 1. 185(5):575-83. [Medline].

  16. Perrin C. A patient with acquired immunodeficiency syndrome (AIDS) and a cutaneous Mycobacterium avium intracellulare infection mimicking histoid leprosy. Am J Dermatopathol. 2007 Aug. 29(4):422. [Medline].

  17. Kitada S, Kobayashi K, Ichiyama S, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med. 2008 Apr 1. 177(7):793-7. [Medline].

  18. [Guideline] Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15. 175(4):367-416. [Medline]. [Full Text].

  19. Kasperbauer SH, Daley CL. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin Respir Crit Care Med. 2008 Oct. 29(5):569-76. [Medline].

  20. Davis KK, Kao PN, Jacobs SS, et al. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med. 2007 Feb 23. 7:2. [Medline].

  21. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology. 2007 Jun. 132(7):2313-9. [Medline].

  22. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006 Jun 1. 173(11):1283-9. [Medline].

  23. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest. 2003 Oct. 124(4):1482-6. [Medline].

  24. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008 Jul. 63(7):627-34. [Medline].

  25. [Guideline] Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr. 58:1-207. [Medline].

  26. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS. 1997 Mar. 11(3):311-7. [Medline].

  27. de Silva TI, Cope A, Goepel J, et al. The use of adjuvant granulocyte-macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection. J Infect. 2007 Apr. 54(4):e207-10. [Medline].

  28. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996 Aug 8. 335(6):384-91. [Medline].

  29. Lindeboom J. Conservative wait-and-see therapy versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis. Jan 15 2011. 52(2):180-4.

  30. Ichikawa K, van Ingen J, Koh WJ, Wagner D, Salfinger M, Inagaki T, et al. Genetic diversity of clinical Mycobacterium avium subsp. hominissuis and Mycobacterium intracellulare isolates causing pulmonary diseases recovered from different geographical regions. Infect Genet Evol. 2015 Oct 2. [Medline].

CT thorax of a 77-year-old woman who presented with chronic cough and sputum production, without a history of underlying pre-existing lung disease. Sputum culture grew Mycobacterium avium complex. The diagnosis was Lady Windermere syndrome.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.